US regulators have approved a combination of AbbVie and Roche’s Venclexta in combination with Roche/Biogen’s Rituxan (rituximab) to treat chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
News
Vertex presents real-world data highlighting benefit of CF drug Kalydeco
Vertex has presented long-term, observational data highlighting the benefit of Kalydeco in patients with cystic fibrosis.
Industry continues to voice its support for the all-new Sales Awards
Following on from Dr Jim Golby’s comments only last week, David Garmon-Jones, co-chair of the competition’s executive steering group (ESG) is also calling on all pharma sales professionals to get involved in the competition.
Are you an agency that has strong experience in dealing with UK specific challenges?
With spaces in the Communications Team of the Year competition filling up fast, agencies are advised to act now and get their entry for the NHS Challenge in before it’s too late!
US widens scope of Rituxan to include life-threatening skin condition
Roche group Genentech has received US approval for Rituxan to treat moderate to severe pemphigus vulgaris (PV), giving patients access to the first new therapy for the condition in more than 60 years.
Pfizer files PARP inhibitor for breast cancer in US, EU
Regulators on both sides of the Atlantic have accepted for review Pfizer’s PARP inhibitor talazoparib as a treatment for women with a hereditary BRCA mutation.
Pfizer, Flynn Pharma win appeal against CMA’s £90m fine
The Competition Appeal Tribunal in the UK has overturned a £90 million fine for Pfizer and Flynn Pharma issued by the Competition and Markets Authority for charging unfair prices for phenytoin sodium capsules.
Boehringer’s Spiriva gets UK license for young asthma patients
Boehringer Ingelheim’s Spiriva Respimat is now licensed for use in the UK to treat people with asthma aged six years and older.
High court rejects homeopathy plea
The High Court has rejected a legal challenge by the British Homeopathy Association to block plans to no longer routinely fund homeopathy on the NHS.
UK health spends lags behind EU peers
The amount the UK spends on health falls well behind that invested by European peers such as Germany and France, according to a report commissioned by the NHS Confederation
NICE deems MSD’s Keytruda cost-effective as first-line lung cancer therapy
MSD’s Keytruda will be routinely available on the NHS for specific patients with previously untreated metastatic non-small-cell lung cancer, after NHS England struck a deal with the company, endorsed by NICE, to ensure its cost-effectiveness.
Pfizer unveils $600m investment in venture capital arm
Pfizer is planning to invest $600 million in biotechnology and other emerging growth companies through its venture investment group.
NICE rejects Janssen’s Zytiga for early, aggressive prostate cancer
It is looking unlikely that Janssen’s Zytiga plus androgen deprivation therapy and prednisone/prednisolone will become routinely available on the NHS as a first-line treatment for patients with high-risk hormone-sensitive metastatic prostate cancer.
US nod for Alimta/Keytruda lung cancer combo
US regulators have approved a combination of Eli Lilly’s Alimta and MSD’s Keytruda as first-line treatment for patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status.
Priority review for Roche’s Hemlibra
Roche’s Hemlibra will get a speedy review in the US for adults and children with haemophilia A without factor VIII inhibitors.
